One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

All news

Archive

✕

21 March 2022

2439

For Life4me+ 2021 was all about “Respect my HIV”

For Life4me+ 2021 was all about “Respect my HIV”

For Life4me+, 2021 was a very busy year. Despite the fact that everyone had to learn to live in the reality of COVID-19, it was a year of scientific success in the field of HIV - after the stagnation of 2020. 2021 was a year of new information projects and conferences ...

21 March 2022

1901

Asymptomatic tuberculosis more common in people living with HIV

Asymptomatic tuberculosis more common in people living with HIV

A study, conducted in South Africa, has found that the incidence of subclinical (asymptomatic) tuberculosis is higher in people living with HIV and similar to that of those with clinical tuberculosis (TB). The study was published in Healio Magazine. These findings have ...

14 March 2022

2463

‘Dare to share care’ campaign launched to support HIV care in Ukraine

‘Dare to share care’ campaign launched to support HIV care in Ukraine

Europe is home to almost three million people living with HIV, with over 250,000 of those living in Ukraine. The invasion of Ukraine and the armed conflict have threatened the care for those quarter of a million people. The Young Investigators (YING) in partnership with ...

11 March 2022

2164

Cabotegravir: Every other month dosing may carry viral load risks

Cabotegravir: Every other month dosing may carry viral load risks

Clinical trial researchers have found that people who received injectable cabotegravir (Vocabria) and rilpivirine (Rekambys) every other month maintained viral suppression just as well as those who received the drug monthly, but patients on the every other month dosing schedule ...

11 March 2022

2154

Geographical modelling and HIV transmission

Geographical modelling and HIV transmission

Sexual interactions between people from different communities might explain why HIV prevention efforts targeting single communities weren’t as effective has expected. This is according to a study, published in eLife. Magus and his colleagues based their research on HIV ...

11 March 2022

1790

Link shown between PrEP use and loss of bone density

Link shown between PrEP use and loss of bone density

It has been known for some time that use of Truvada, and generic versions of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), has been associated with the loss of bone density in people living with HIV. But there has been a lack of data on how the drug combination ...

11 March 2022

1751

How does the microflora of male genitalia system affect HIV infection?

How does the microflora of male genitalia system affect HIV infection?

Scientists at the George Washington University in the United States are launching a new study to determine what role the microbiome (microflora) of the urogenital tract might play in HIV infection. The purpose of the five-year trial is to find new solutions aimed at reducing ...

11 March 2022

1468

Integrase inhibitors connected to a higher risk of hypertensions in people living with HIV

Integrase inhibitors connected to a higher risk of hypertensions in people living with HIV

The RESPOND study, involving more than 30,000 people living with HIV from 17 cohorts, has confirmed the link between the link of integrase inhibitors (INSTI) and the incidence of hypertension. The research results have been presented by our parters at the European AIDS Treatment ...

11 March 2022

1934

FDA denies Lenacapavir approval due to issues with glass vials

FDA denies Lenacapavir approval due to issues with glass vials

The Food and Drug Administration (FDA) has refused to approve an antiretroviral HIV treatment from Gilead Sciences due to concerns about the glass vials used to store the treatment, reports Reuters, citing Gilead’s statement. In a full response, the FDA highlighted issues ...

28 February 2022

2657

Work underway to assist Ukrainian people with continued access to HIV treatment

Work underway to assist Ukrainian people with continued access to HIV treatment

Amid the conflict in Ukraine, people are experiencing difficulties accessing HIV treatment, care and related services. Many organisations, including NGOs, have mobilised with the goal of ensuring uninterrupted access to antiretroviral therapy for all who need it. Winnie ...

1...6 7 8 9 10...116